CRYO CELL INTERNATIONAL INC (CCEL) stock intrinsic value fair value estimate & owner earnings analysis

Cryo-Cell International, based in Oldsmar, Florida, is one of the oldest private umbilical cord blood and cord tissue banks in the United States. Its fiscal year ends in November. Parents pay a processing fee at birth and then either an annual storage fee or a lump sum for an 18-year or lifetime plan. The company stores specimens in Florida and in a 56,000 square foot building it acquired and fitted out in Durham, North Carolina in 2022-2024. Revenue has been essentially flat at $29-32 million a year since 2019 ($31.6 million in fiscal 2025). How we measured earnings. The cash flow statement flatters this business. Each year prepaid storage plans bring in about $4-5 million more cash than is recognised as revenue, and the deferred-revenue balance has grown from $32.5 million in 2019 to $60.7 million in 2025 ($63.9 million by August 2026). That cash is real, but it is a prepayment for decades of storage the company still has to provide. So we removed it from the yearly earning power and valued it separately. On that basis the business earned about $1.9-3.1 million a year in 2017-2020, before the Duke program, after stock pay and equipment replacement. That is roughly $0.21-0.38 a share. Fiscal 2021-2025 were distorted by the Duke University license and the Durham building, about $21 million of capital spending in 2021-2024, plus license payments, write-downs and legal costs. Owner earnings were negative in 2022-2024 and $0.7 million ($0.09 a share) in 2025, a year that also carried Duke arbitration costs. We anchor on about $2.1 million a year, which is roughly $2.0 million of owner earnings plus interest of about $0.5-0.9 million a year on the bank loans. This is the pre-Duke 2017-2020 range, adjusted for today's slightly lower revenue. The first year is held at $1.6 million because arbitration costs continued in 2026 (Duke-related legal costs rose about $2 million year to date). Fiscal 2025 grew from a negative base, so we credit no growth beyond returning to the level the business has already shown. Nine-month 2026 results (net income $1.9 million, operating cash flow $3.6 million, capital spending $0.2 million, no dividends) are consistent with this. What it owes. The company owes about $8.2 million on a Susser Bank term loan maturing July 2032. It pays SOFR plus 3.25%, about 7.5-8%. The $8 million revolver, extended to October 2027, was fully repaid by August 2026. Against this it holds $1.4 million of cash and $2.8 million of marketable securities. After keeping $1 million for operations and charging about $0.6 million for the loan costing more than 6% over its life, net debt is about $5.6 million, or $0.70 a share. A $0.9 million legacy revenue-sharing liability is already paid through operating cash flow and is not subtracted again. The large deferred-revenue liability is handled through the storage obligation in each case, not as debt. Base case: storage earnings recover to about $2.1 million a year (business stream before lenders) from fiscal 2027, flat for ten years and then fading 3% a year. Storage contracts run 18 years to life, so the existing customer base keeps paying long after new sign-ups slow, while U.S. births and cord-banking take-up are flat to declining. Prepaid plans keep adding net cash early on, credited at $1.6 million a year and tapering to nothing over ten years. The business is worth about $34 million, it owes about $5.6 million net, and that leaves about $28 million, or $3.50 a share. Bear case: the Duke arbitration, with a final hearing set for April 2026 and the outcome still pending, goes against the company, costing about $2 million in fiscal 2027 on top of legal fees already incurred. Duke has counterclaimed for breach of the license and indemnity. Then comes a consumer downturn like the 2020 shutdown. Fiscal 2020-2021 revenue fell 9% from its 2019 peak, and an elective prepaid purchase is exactly what families defer. We model two years of earnings down by about 30%, and prepaid cash running backwards by $1 million a year in those years. Afterwards earnings settle at $1.5 million, declining 3% a year, with net prepaid run-off of $0.6 million a year from year 11 as fewer new families sign up. The company also received an exchange notice in March 2026 for a stockholders' deficit (minus $16.4 million in August 2026) and losses in two of its last three years. A delisting would reduce liquidity for shareholders but would not change the cash the business produces. The business is worth about $9.9 million, it owes $5.6 million net, and that leaves about $4.3 million, or $0.53 a share. This case still covers its interest bill in every year. Bull case: arbitration costs end after fiscal 2026 without a damaging award, and storage earnings return to about $3.0 million. That is the top of the 2019-2020 range, when revenue was $31-32 million, as it is now. Earnings hold for ten years and then fade 2% a year. Prepaid plans keep adding $2.5 million of net cash for five years before tapering. Any damages the company might win from Duke (it claims over $100 million) are left out of every case because nothing in the filings makes recovery likely. The business is worth about $57 million, it owes $5.6 million net, and that leaves about $51 million, or $6.37 a share. Margin-of-safety price. We are moderately sure of the earnings level. The 2017-2020 record is consistent, and recent quarters (capital spending back to about $0.2-0.3 million a year, net income positive in fiscal 2026) suggest the core storage business is intact. The Duke program is the unknown. The worst plausible outcome is a large arbitration award to Duke combined with a slump in new enrollments. That would leave a company with $8 million of bank debt, thin cash, and a $64 million obligation to keep storing specimens for decades. The structure would survive a mild version, because the recurring annual storage fees are sticky and the loan is long-dated. A severe award could force dilution. If we are wrong about the level ($1.5 million instead of $2.1 million) and the float (no net prepaid cash at all), the shares are worth roughly $1.50-2.00. During the holding period the company pays nothing: dividends stopped in 2025 and buybacks stopped. The price assumes value is reflected within four to five years. From $1.50 a share, even an outcome halfway between the bear and base cases implies 20% a year over five years if the base case is approached. A share price at the bear-case level would mean loss of most of the capital at that price, which we judge to be a roughly one-in-ten outcome. The margin-of-safety price is $1.50. Our previous estimate measured earnings on a different basis, so its figures are not comparable. The main change in the business since then: the company repaid its $2.3 million revolving credit line, suspended its dividend, and received an exchange listing notice. Duke counterclaims remain unresolved.